External Pacemaker Market: as CMS Medicare cardiac equipment reimbursement of USD 620.30 Million for external pacemakers in 2023 and Germany EUR 1.40 Billion arrhythmia device budget in 2024 establish the payor frameworks sustaining acute cardiac surgery and AV block pacing demand, Medtronic CRHF FY2025 revenue of USD 6.39 Billion at 7% growth led by Micra high-teens and SelectSecure 3830 volume confirms the commercial trajectory of the broader cardiac rhythm management ecosystem, so demographic aging creates a structurally expanding AV block and post-cardiac-surgery patient population requiring temporary external pacing across acute care settings globally.

The global external pacemaker market size was USD 1.86 Billion in 2025 and is expected to register a revenue CAGR of 4.8% during the forecast period. Market revenue growth is driven by factors such as CMS and European payor frameworks sustaining reimbursement for acute cardiac pacing across hospital cardiac surgery and intensive care settings, Medtronic CRHF FY2025 performance confirming sustained cardiac rhythm management commercial momentum, and as well as the structurally expanding patient population of aging adults with AV block and post-cardiac-surgery pacing requirements across global acute care hospital networks. The first driving factor is the CMS Medicare cardiac equipment reimbursement framework that allocated USD 620.30 Million specifically to external pacemakers in 2023 within the broader USD 4.20 Billion cardiac equipment category, establishing a non-discretionary per-procedure payor commitment that sustains external pacemaker capital and disposable consumable demand at US hospital cardiac surgery departments and intensive care units independently of hospital discretionary capital budget cycles. The second driving factor is Medtronic CRHF segment FY2025 revenue of USD 6.39 Billion at 7% growth, with the FY2024 10-K disclosing USD 5.99 Billion, and Micra transcatheter pacemaker revenue growing high-teens as SelectSecure 3830 lead volumes confirm the expanding cardiac pacing procedure base at interventional cardiology centres globally, demonstrating that the payor and procedure volume infrastructure sustaining broader cardiac rhythm management commercial growth also supports the adjacent external temporary pacing segment. The third driving factor is the demographic aging trend creating a structurally expanding patient population of adults over 65 requiring temporary external pacing during AV block episodes, post-cardiac-surgery epicardial pacing protocols, and pre-implant bridging therapy before permanent pacemaker placement at hospital cardiac electrophysiology and surgery departments. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way hospital cardiac surgery programme volume growth compounds external pacemaker consumable demand across the installed equipment base, which allows transvenous temporary pacemaker capital placements from the prior decade to generate continuing per-procedure lead and accessory consumable revenue without requiring equivalent capital equipment replacement cycles. Once a hospital cardiac surgery department installs a transvenous temporary pacing system, each post-operative cardiac surgery patient requiring temporary pacing represents a pacing lead and cable consumable revenue event that compounds over the full pacing episode duration until the temporary pacing indication resolves or permanent pacing is indicated, so the external pacemaker consumable revenue per hospital grows in direct proportion to cardiac surgery programme volume expansion. As a result, demand and revenue share are concentrating around the vendors with the broadest hospital cardiac surgery department commercial relationships and the most comprehensive pacing lead and accessory consumable portfolios, and the forecast tilts toward these established system-and-consumable platform vendors rather than standalone capital equipment competitors without equivalent service and accessory infrastructure. For instance, in April 2025, Medtronic received FDA approval for the OmniaSecure leadless pacemaker system, which as a permanent pacing solution sustains the clinical and commercial infrastructure around temporary external pacing as the bridge-to-permanent-implant modality at hospital cardiac electrophysiology programmes. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the established payor reimbursement framework for temporary cardiac pacing at US and European hospital cardiac surgery and intensive care departments, which creates non-discretionary per-procedure revenue certainty that sustains external pacemaker capital and consumable demand across the installed hospital cardiology infrastructure base. Reimbursement-driven demand works commercially because CMS Medicare cardiac equipment reimbursement allocating USD 620.30 Million specifically to external pacemakers within the cardiac equipment category creates a predictable per-procedure payment stream that hospital procurement committees recognise as non-discretionary patient care expenditure, so temporary pacemaker procurement is protected from hospital cost-containment pressure that affects elective procedure device categories. Germany's EUR 1.40 Billion arrhythmia device budget in 2024 similarly establishes a national payor commitment to cardiac rhythm management that sustains both temporary and permanent pacing device procurement across the German hospital system. Medtronic CRHF FY2024 revenue of USD 5.99 Billion per the company's Form 10-K and FY2025 revenue of USD 6.39 Billion at 7% growth reflect the commercial scale of the cardiac rhythm management segment anchoring the temporary pacing ecosystem, with CRHF encompassing external and temporary pacing alongside implantable pacing products. Japan's NHI system similarly provides comprehensive cardiac device reimbursement that sustains temporary external pacing procurement at Japanese tertiary hospital cardiac surgery departments. These are some of the key factors driving revenue growth of the market.

The second driver is the expanding permanent pacemaker implantation procedure volume that sustains the adjacent temporary external pacing bridge demand at hospital electrophysiology and cardiac surgery programmes, because most patients requiring permanent pacemaker implantation require temporary external pacing during the peri-procedural period between arrhythmia diagnosis and permanent pacemaker placement. Procedural bridge pacing works commercially because each new permanent pacemaker patient pathway at a hospital electrophysiology programme represents an external temporary pacemaker usage episode generating lead and consumable revenue while the patient awaits permanent device implant, and the growth of permanent pacing procedure volumes driven by demographic aging and expanded electrophysiology programme capacity at regional hospitals directly expands the addressable temporary pacing episode volume. Medtronic FY2025 CRHF revenue of USD 6.39 Billion at 7% growth, with Micra transcatheter pacemaker growing high-teens and SelectSecure 3830 lead volume expanding the single-lead pacing patient population, confirms that permanent cardiac pacing procedure volumes are growing at the US and global hospital electrophysiology programme base that generates external pacing bridge demand. In April 2025, Medtronic received FDA approval for OmniaSecure, a fully leadless pacemaker system, continuing the permanent pacing innovation cycle that generates the new patient cohorts who require temporary external pacing bridge before device implant. These are some of the key factors driving revenue growth of the market.

CMS Medicare cardiac equipment reimbursement allocated USD 620.30 Million specifically to external pacemakers in 2023, within the broader USD 4.20 Billion cardiac equipment category. This per-procedure payor commitment protects temporary pacemaker procurement from hospital capital budget constraints and sustains consumable demand at US hospital cardiac surgery and intensive care departments independent of discretionary capital spending cycles, which is why the external pacemaker market maintains stable 4 to 5% CAGR through economic cycles that disrupt elective procedure device markets.

The third driver is the structural expansion of the external pacemaker patient population driven by global demographic aging, as adults over 65 represent both the highest prevalence demographic for conduction system disease requiring temporary external pacing and the fastest-growing age cohort in North American, European, and Asia Pacific developed market populations. Aging-driven demand works commercially because the prevalence of AV block, sick sinus syndrome, and other conduction system diseases that require temporary external pacing before permanent device implant or during acute illness management increases with age in a near-linear relationship, so each percentage point increase in the proportion of population over 65 directly expands the addressable external pacemaker patient volume at each hospital cardiac care unit. The Medtronic FY2025 CRHF 7% growth trajectory at the world's largest cardiac rhythm management company demonstrates that age-related cardiac rhythm demand is growing faster than the underlying healthcare expenditure baseline, confirming demographic aging as the primary structural demand driver. Post-cardiac-surgery epicardial pacing is a second aging-driven demand channel, as cardiac surgery volume in older patients undergoing coronary artery bypass grafting, valve repair, and structural heart procedures generates consistent epicardial pacemaker wire and external pacing generator usage at cardiac surgery departments globally. The effect on the market is that the structural aging of the patient population creates a compounding annual external pacemaker volume growth rate that is largely independent of technology innovation cycles and driven primarily by the demographic expansion of the AV block and post-cardiac-surgery patient population. These are some of the key factors driving revenue growth of the market.

However, the external pacemaker market faces adoption constraints from leadless pacemaker expansion shortening temporary pacing bridge periods and competitive substitution from defibrillator-pacemaker combination systems. Because Medtronic Micra high-teens revenue growth and OmniaSecure FDA approval in April 2025 confirm that leadless pacemaker adoption is expanding at high-volume implant centres where streamlined implant pathways reduce the temporary external pacing bridge period per patient before permanent device placement, the per-patient temporary pacemaker consumable revenue contribution is progressively declining at those accounts even as overall permanent pacing procedure volume grows. Competitive substitution is a second constraint, as external defibrillators with integrated transcutaneous pacing capability including Stryker LIFEPAK 35 and ZOLL AED 3 systems equip hospital emergency departments and intensive care units with transcutaneous pacing functionality within the defibrillation device, reducing the standalone external transcutaneous pacemaker procurement need at settings where combined defibrillation-pacing functionality addresses both clinical requirements in a single capital investment. Reimbursement constraints in emerging markets are the third constraint, where inconsistent payor frameworks for temporary cardiac pacing at public hospital settings in Asia Pacific, Latin American, and Middle East and Africa markets limit the external pacemaker addressable market to private hospital and tertiary care settings. These factors substantially limit external pacemaker market growth over the forecast period.

Based on product, the global external pacemaker market is segmented into transvenous temporary pacemakers, transcutaneous external pacemakers, epicardial pacing systems, and pacing leads and accessories. Transvenous temporary pacemakers hold the largest revenue share at approximately 52%, driven by hospital cardiac surgery and electrophysiology programme usage of transvenous pacing generators and leads as the primary bridge-to-permanent-pacemaker and post-cardiac-surgery pacing modality. Medtronic 5388 temporary pacemaker and Biotronik external temporary pacemakers represent the primary transvenous pacing generator platforms at US and European hospital cardiac care departments. Epicardial pacing systems are expected to register a rapid revenue growth rate in the global external pacemaker market over the forecast period, driven by expanding cardiac surgery volume at regional hospital programmes generating post-operative epicardial pacing wire usage.

Based on end-use, the global external pacemaker market is segmented into hospitals and cardiac surgery units, intensive care units, and emergency departments and pre-hospital settings. Hospitals and cardiac surgery units hold the largest revenue share, processing the highest external pacemaker usage volume at cardiac surgery, interventional cardiology, and cardiac electrophysiology departments where both transvenous bridge pacing and epicardial post-surgical pacing generate consistent consumable demand. Intensive care units are expected to register a rapid revenue growth rate in the global external pacemaker market over the forecast period, driven by expanding critical care cardiac monitoring protocols at hospital ICUs treating post-cardiac surgery patients, sepsis-related arrhythmias, and drug-induced conduction disease requiring temporary external pacing management.

Based on regional analysis, the external pacemaker market in North America accounted for largest revenue share in 2025. The United States drives the regional position through CMS Medicare cardiac equipment reimbursement of USD 620.30 Million for external pacemakers in 2023, Medtronic's US-anchored CRHF commercial infrastructure, and the high density of hospital cardiac surgery and interventional cardiology programmes generating consistent temporary pacing bridge demand. Medtronic FY2025 CRHF revenue of USD 6.39 Billion at 7% growth confirms the sustained commercial momentum of the US cardiac rhythm management market that anchors external temporary pacing demand. The Asia Pacific external pacing supply chain is not materially affected by Iran-US sanctions given that primary pacemaker component and generator manufacturing is concentrated in North American, European, and Japanese facilities outside Strait of Hormuz logistics corridors.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and Italy represent the four largest national external pacemaker markets in Europe. Germany's EUR 1.40 Billion arrhythmia device budget in 2024 establishes the national payor commitment that sustains external pacemaker capital and consumable procurement across the German hospital cardiac programme network. Biotronik, headquartered in Berlin, Germany, is the primary European external temporary pacemaker manufacturer with established hospital cardiology department commercial relationships across the German, Italian, and Benelux markets. The EU Medical Device Regulation compliance requirement for external pacemakers creates an additional regulatory validation hurdle above the pre-2021 MDD framework, adding compliance cost for temporary pacemaker manufacturers maintaining European hospital market access.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, South Korea, and Australia represent the four largest national external pacemaker markets in the region. Japan's NHI reimbursement for cardiac devices sustains external temporary pacemaker procurement at Japanese tertiary hospital cardiac surgery departments and electrophysiology programmes performing the highest volume of permanent pacemaker implant procedures in the region. China's expanding hospital cardiac surgery and electrophysiology programme infrastructure at tier 2 and tier 3 city provincial hospitals is creating demand for external temporary pacemaker capital and consumable procurement as cardiac surgery programme capacity expands.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national external pacemaker markets. Brazil has an established private hospital cardiac surgery programme network in major urban centres requiring external temporary pacemaker capital and consumable procurement, with Medtronic and Biotronik the primary vendors at Brazilian hospital cardiac programmes.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets. Saudi Vision 2030 healthcare infrastructure investment is expanding cardiac surgery and electrophysiology programme capacity at national hospital networks including King Faisal Specialist Hospital and Research Centre, creating external temporary pacemaker capital and consumable procurement demand at newly commissioned cardiac care units.